The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

(RTTNews) - Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna's ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel ...

Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD) and transfusion-dependent beta ...

Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA ®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in ...

WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid ...

Orna Therapeutics and Shanghai Simnova expand their collaboration to develop RNA-based therapies targeting BCMA for multiple ...

SHANGHAI and CAMBRIDGE, Mass. , Jan. 15, 2025 /PRNewswire/ -- Orna Therapeutics, Inc. ("Orna") and Shanghai Simnova Biotech Co., Ltd. ("Simnova") are pleased to ...